The effect of adaptive servo ventilation therapy on cardiovascular disease in heart failure patients with cardiac implantable electronic devices.

The effect of adaptive servo ventilation therapy on cardiovascular disease in heart failure patients with cardiac implantable electronic devices. - The effect of adaptive servo ventilation therapy on cardiovascular disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010076

Enrollment

Registered

2013-02-20

Start date

2013-02-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failuree

Interventions

Group1

Adaptive servo ventilation therapy from Day 1 to Day 90. After that, we crossover the patients and stop the adaptive servo ventilation therapy from Day 91 to Day 180. Group2

No adaptive servo ventilation therapy from Day 1 to Day 90. After that, we crossover the patients and start the adaptive servo ventilation therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) At the age of 20 or above (at consent acquisition) (2) Patients with cardiac implantable electronic devices (Pace maker, ICD and CRT-D). (3)Heart failure patients whose EF is 45% or less than 45%. (4) Patients with standard optimal drug therapy (beta blocker, ACEI/ARB, etc) who did not any episode of admission due to decompensated heart failure within 3 months. (5) Patients who give written consent to participation in the study at their own will.

Exclusion criteria

Exclusion criteria: (1) Patients with cancer, severe infection and traumatic disease. (2) Other patients deemed unsuitable by the principal investigator or investigator.

Design outcomes

Primary

Measure	Time frame
Absolute and percent changes in frequencies of arrythmia(atrial or ventricular arrhythmia) that are stored in the cardiac implantable electronic devices.	—

Secondary

Measure	Time frame
To assess the concomitant effects of the adaptive servo ventilation therapy and their mechanisms, we also evaluate the absolute and percent changes in following parameters; cardiac function assessed by echocardiography, endothelial function (Endo-PAT2000), oxidative stress markers (dROM/BAP etc), sleep disorder breathing (AHI), exercise capacity (5m gait speed), metabolic status (lipid/glycemic parameters), renal function, symptom/QOL, impedance assessed by devices, body weight, drug component, Prognosis (death, heart failure, etc)	—

Measure

Time frame

To assess the concomitant effects of the adaptive servo ventilation therapy and their mechanisms, we also evaluate the absolute and percent changes in following parameters; *cardiac function assessed by echocardiography, *endothelial function (Endo-PAT2000), *oxidative stress markers (dROM/BAP etc), *sleep disorder breathing (AHI), *exercise capacity (5m gait speed), *metabolic status (lipid/glycemic parameters), *renal function, *symptom/QOL, *impedance assessed by devices, *body weight, *drug component, *Prognosis (death, heart failure, etc)

—

Countries

Japan

Contacts

Public ContactKozo Okada

Yokohama City University Medical Center Division of Cardiology

kozookada@gmail.com045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026